[Feasibility and change in the level of blood paclitaxel concentration after paclitaxel therapy for a hemodialysis patient with cisplatin resistant metastatic transitional cell cancer].
The patient was a 54-year-old woman with recurrent urinary tract cancer. A CT of the lung showed multiple nodules after bil-nephroureterectomy, cystectomy and combination chemotherapy with cisplatin (CDDP) and epirubicin (EPI). As second line chemotherapy for the patient, TXL was administered. She was hemodialized after operation, and there are few reports about paclitaxel (TXL) therapy for hemodialysis (HD) patients. Peak blood TXL concentration, about 1,200 ng/ml, was achieved 6 hours after the administration of TXL. The blood TXL concentration was 41 ng/ml 24 h after the administration of TXL. However, the TXL therapy was not repeated because of unacceptable neurological side effects. An almost 40% shrinkage in the size of the metastatic lung nodule was obtained after 1 cycle of treatment.
Nomata
Koichiro
K
Dept. of Urology, Nagasaki University School of Medicine.
Sagara
Yuzi
Y
Toubu
Syohhei
S
Hakariya
Tomoaki
T
Tsuda
Satoshi
S
Noguchi
Mitsuru
M
Eguchi
Jiro
J
Kanetaka
Hiroshi
H
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000097:blood*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000494:pharmacology; D015653:Cystectomy; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage* / Q000097:blood*; D006435:Renal Dialysis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel; D002945:Cisplatin